CR10014A - Derivados de 3-alquilazetidina sustituidos con heterociclos. - Google Patents

Derivados de 3-alquilazetidina sustituidos con heterociclos.

Info

Publication number
CR10014A
CR10014A CR10014A CR10014A CR10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A
Authority
CR
Costa Rica
Prior art keywords
alquilazetidina
heterocicles
derivatives
substituted
receptor
Prior art date
Application number
CR10014A
Other languages
English (en)
Inventor
Robert K Baker
Jeffrey J Hale
Shouwu Miao
Kathleen M Rupprecht
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR10014A publication Critical patent/CR10014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor cannabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple.
CR10014A 2005-11-28 2008-05-22 Derivados de 3-alquilazetidina sustituidos con heterociclos. CR10014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28

Publications (1)

Publication Number Publication Date
CR10014A true CR10014A (es) 2008-07-29

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10014A CR10014A (es) 2005-11-28 2008-05-22 Derivados de 3-alquilazetidina sustituidos con heterociclos.

Country Status (15)

Country Link
EP (1) EP1954692A1 (es)
KR (1) KR20080073721A (es)
AR (1) AR058199A1 (es)
BR (1) BRPI0619018A2 (es)
CR (1) CR10014A (es)
DO (1) DOP2006000261A (es)
EC (1) ECSP088477A (es)
IL (1) IL191586A0 (es)
MA (1) MA30086B1 (es)
NO (1) NO20082919L (es)
PE (1) PE20070647A1 (es)
RU (1) RU2008126248A (es)
SV (1) SV2009002917A (es)
TW (1) TW200804317A (es)
WO (1) WO2007062193A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2703465A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
AU2004252109B2 (en) * 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
AU2006242219A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
ECSP088477A (es) 2008-06-30
PE20070647A1 (es) 2007-08-11
NO20082919L (no) 2008-08-27
AR058199A1 (es) 2008-01-23
EP1954692A1 (en) 2008-08-13
IL191586A0 (en) 2008-12-29
BRPI0619018A2 (pt) 2016-11-29
DOP2006000261A (es) 2007-07-15
KR20080073721A (ko) 2008-08-11
WO2007062193A1 (en) 2007-05-31
RU2008126248A (ru) 2010-01-10
TW200804317A (en) 2008-01-16
MA30086B1 (fr) 2008-12-01
SV2009002917A (es) 2009-02-19

Similar Documents

Publication Publication Date Title
CR10014A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos.
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
DK2049529T3 (da) Substituerede diazepan-orexin-receptor- antagonister
GT200900300A (es) Antagonistas piridil piperidina del receptor de orexina
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
CR20130214A (es) Antagonistas del receptor del cgpr de piperidinona carboxamida azaindano
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
AR036302A1 (es) Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion en el tratamiento de la enfermedad de parkinson
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
GEAP202014908A (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
CL2008002506A1 (es) Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer.
AR036303A1 (es) Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion para el tratamiento de la enfermedad de parkinson
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1112227T1 (el) Πιπεριδινυλαμινο-πυριδαζινες και η χρηση τους ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
GEAP202115141A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
SV2011003839A (es) Agentes antifungicos
ATE466853T1 (de) Cgrp-rezeptorantagonisten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)